Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Starbucks

Global stocks are an excellent way to get exposure to emerging growth markets like India. Another advantage is their diversification across geographic regions, which promotes revenue stability.

Global Giants: 3 Multinational Corporations to Outperform in 2024

The pharmaceutical company has two new research partners. It signed separate but similar deals with Omega Therapeutics and Cellarity.

Why Novo Nordisk Stock Crushed the Market Today

Apple

Mobileye Global Inc

Stocks are fighting tooth and nail to stay in positive territory today, as the sluggish start  to 2024 continues.

Pharma Stock Surges on New Drug Partnerships

Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two American biotech firms.

Novo Nordisk Stock Hit a Record on Thursday. Here's Why.

Novo Nordisk inked a pair of deals Thursday to bolster its weight-loss drugs franchise, and sent shares of Omega into the stratosphere.

Novo Nordisk, The Weight-Loss Kingpin, Inks Two New Obesity Deals

Omega Therapeutics

Omega Therapeutics shares surged more than 100% after it was announced it is partnering with Danish healthcare company Novo Nordisk (NYSE:NVO) to develop novel treatment approaches for cardiometabolic diseases. Novo Nordisk (NYSE:NVO) said that its collaboration with Omega will develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

Omega Therapeutics shares surge on obesity collaboration with Novo Nordisk

Novo Nordisk NVO, +1.48% NOVO.B, +1.88% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management. The Danish developer of weight-loss drugs Ozempic and Wegovy said the Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller that aims to enhance metabolic activity.

Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity management

Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more treatments for cardiometabolic diseases.

Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms

Novo Nordisk (NYSE:NVO) was the European stock market success of last year, on the back of its anti-obsecity drug Wegovy/Ozempic, but analysts at Jefferies wonder if the valuation may be nearing the top as rivals including Pfizer and AstraZeneca work on rival weight loss drugs. 2024 is expected to see at least 20 possible clinical updates in obesity from 10 or more companies, which the investment bank said highlights the potential for significant competition facing Novo and Eli Lilly in the future Jefferies maintains an 'underperform' rating on the Danish drugmaker, saying it is the "least preferred" big cap stock in the sector, though they do not see a single event to catalyse a significant de-rating in the shares.

Novo Nordisk faces number of overlooked trends including competition for Wegovy, warns investment bank

Eli Lilly

Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company is struggling to meet the soaring demand. Expenditures on obesity drugs may eventually exceed spending on food, becoming an important indicator of a country's wealth and standard of living.

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

ARM Holdings PLC

Costco

SPDR Gold Trust

NVIDIA

Palantir Technologies

Plug Power

Tesla

7 Investments To Avoid In 2024

Axsome Therapeutics

Vertex Pharmaceuticals

Axsome Therapeutics could be in store for a breakout year in 2024. Novo Nordisk remains cheap, considering its growth prospects.

Prediction: These 3 Stocks Will Soar in 2024

CME Group

Johnson & Johnson

Coca-Cola

Lockheed Martin

Novartis

PepsiCo

Procter & Gamble

Roche Holding AG

Raytheon Technologies

SPDR S&P 500 ETF Trust

I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.

Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks

Amgen

Pfizer

Things could hardly have gone worse for healthcare investors this year.

Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.

AbbVie

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively.

Pharmaceutical stocks to watch in 2024

Demand for Novo Nordisk's weight-loss products has become so significant that the company is investing billions into building more capacity. Meta Platforms has been one of the best-performing stocks this year, but it could face challenges.

Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?

The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may still be available for purchase.

Novo Nordisk, FDA warn of fake Ozempic

The U.S. Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.

US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic

Nutrien

Palo Alto Networks

Travelers

Visa

Nintendo

At first glance, targeting low-volatility stocks to buy for stable growth might seem too cautious. Yet, in the investment world, keeping tabs on volatility is imperative and a key indicator of risk.

7 Low-Volatility Stocks for Stable Growth in 2024

AstraZeneca

The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry

Investing early in an emerging field can sometimes lead to outsize returns. Medicines that extend life spans are going to be big someday.

Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.

An article in "The New York Times" pointed out that Ozempic and Wegovy's active ingredient could have other healing properties. It could help with ovarian disorders, for example, or even help combat alcoholism.

Why Novo Nordisk Stock Was Up on a Down Day for the Market

Altimmune

Structure Therapeutics Inc

Viking Therapeutics

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Journey Medical Corp

Fusion Pharmaceuticals

Lyra Therapeutics

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

Novo Nordisk is the developer behind Ozempic and Wegovy, both of which are seeing unprecedented demand. Eli Lilly's Mounjaro is challenging the competition, generating over $3 billion in sales since its launch last May.

These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond

News for Novo Nordisk Stock (NVO)